Literature DB >> 12602528

Orbital radiotherapy for Graves' ophthalmopathy: useful or useless? Safe or dangerous?

L Bartalena1, C Marcocci, C A Gorman, W M Wiersinga, A Pinchera.   

Abstract

Treatment of Graves' ophthalmopathy does not always provide favorable results. After several decades of efforts, glucocorticoids, orbital radiotherapy (OR) and surgery (orbital decompression) remain the milestones in the management of this disease. OR produce favorable results in about 55-60% of patients. Its effectiveness is increased by the association with systemic glucocorticoids. Recent studies have cast some doubts on its real effectiveness and this is discussed by participants in this Forum. Selection of patients is particularly important to assess treatment outcome, because OR is unlikely to provide beneficial effects in patients with longstanding and inactive eye disease. OR is a safe procedure, with very limited side-effects. It should be used in patients older than 35 years of age. It is recommended that a large, multi-center, prospective, randomized and controlled study with well defined inclusion criteria be carried out to draw sound conclusions on the role of OR in the management of Graves' ophthalmopathy.

Entities:  

Mesh:

Year:  2003        PMID: 12602528     DOI: 10.1007/BF03345116

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  40 in total

1.  Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial.

Authors:  G J Kahaly; H P Rösler; S Pitz; G Hommel
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  Assessment of a carcinogenic risk for treatment of Graves' ophthalmopathy in dependence on age and irradiation geometry.

Authors:  J J Broerse; A Snijders-Keilholz; J T Jansen; J Zoetelief; C Klein; M H Seegenschmiedt
Journal:  Radiother Oncol       Date:  1999-12       Impact factor: 6.280

Review 3.  Does radiotherapy have a role in the management of thyroid orbitopathy? View 2.

Authors:  Maarten Ph Mourits
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

4.  Smoking and Graves' disease.

Authors:  Luigi Bartalena
Journal:  J Endocrinol Invest       Date:  2002-05       Impact factor: 4.256

5.  Clever is not enough: NOSPECS is form in search of function.

Authors:  C A Gorman
Journal:  Thyroid       Date:  1991       Impact factor: 6.568

6.  Probable risk of tumor induction after retro-orbital irradiation for Graves' ophthalmopathy.

Authors:  L E Blank; G W Barendsen; M F Prummel; L Stalpers; W Wiersinga; L Koornneel
Journal:  Radiother Oncol       Date:  1996-08       Impact factor: 6.280

7.  Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.

Authors:  M N Gerding; C B Terwee; F W Dekker; L Koornneef; M F Prummel; W M Wiersinga
Journal:  Thyroid       Date:  1997-12       Impact factor: 6.568

Review 8.  Orbital radiotherapy for Graves' ophthalmopathy.

Authors:  Luigi Bartalena; Claudio Marcocci; Maria Laura Tanda; Roberto Rocchi; Barbara Mazzi; Giuseppe Barbesino; Aldo Pinchera
Journal:  Thyroid       Date:  2002-03       Impact factor: 6.568

9.  Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.

Authors:  C Marcocci; L Bartalena; F Bogazzi; G Bruno-Bossio; A Lepri; A Pinchera
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

10.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

View more
  7 in total

Review 1.  Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.

Authors:  C Marcocci; M Marinò; R Rocchi; F Menconi; E Morabito; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 2.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

3.  Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.

Authors:  Charlée Nardin; Sophie Borot; Marie-Astride Beaudoin; Françoise Cattin; Eve Puzenat; Anne-Sophie Gauthier; Franck Schillo; Christophe Borg; François Aubin
Journal:  Invest New Drugs       Date:  2018-08-25       Impact factor: 3.850

4.  Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves.

Authors:  M Marinò; E Morabito; M A Altea; E Ambrogini; F Oliveri; M R Brunetto; L E Pollina; D Campani; P Vitti; L Bartalena; A Pincheral; C Marcocci
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

5.  Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not?

Authors:  Aneta Zygulska
Journal:  J Ocul Biol Dis Infor       Date:  2009-10-06

Review 6.  Graves' ophthalmopathy: state of the art and perspectives.

Authors:  L Bartalena; W M Wiersinga; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

7.  Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial.

Authors:  Rathie Rajendram; Richard W J Lee; Mike J Potts; Geoff E Rose; Rajni Jain; Jane M Olver; Fion Bremner; Steven Hurel; Anne Cook; Rao Gattamaneni; Marjorie Tomlinson; Nicholas Plowman; Catey Bunce; Sandra P Hollinghurst; Laura Kingston; Sue Jackson; Andrew D Dick; Nichola Rumsey; Olivia C Morris; Colin M Dayan; Jimmy M Uddin
Journal:  Trials       Date:  2008-01-31       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.